Technical Note: Cybernetic Hematopoiesis and the Wave-Native Eradication of Sickle Cell Disease

This technical note (Version 3.0) formalizes a wave‑native pharmacological architecture for in vivo eradication of Sickle Cell Disease (SCD) without myeloablative conditioning, reframing SCD as a genetic software fault rather than a hardware failure. The work introduces the MetaboJoint Vault, a stimuli‑responsive SBMA‑b‑CBMA block‑copolymer micelle engineered to execute a dual‑condition AND‑gate logic, governed by a bistable potential U(x)=α2x2+β4x4 with β<0 and niche‑specific modulation of the barrier height ΔU. Version 3.0 completes the pre‑experimental computational validation phase through a five‑figure simulation series covering nanoscale vault topology, double‑well energetics, AFM‑predicted rupture forces, and a 90‑minute execution timeline showing pH‑dependent attenuation followed by Cathepsin‑K‑driven transition to full payload elution. A Phase I RAFT‑polymerization protocol (0.1 mmol scale, 70∘C in anhydrous DMF) specifies the synthesis of a 70:30 SBMA:CBMA diblock with defined QC checkpoints and a predicted hydrodynamic diameter of 10±2 nm. The accompanying validation roadmap provides explicit decision gates for in‑vitro, organoid, and in vivo (Townes SCD model) testing, including graph‑theoretic vascular recovery via the Fiedler value λ2. This framework—integrating nonlinear dynamics, stimuli‑responsive polymer chemistry, and network‑level pathology modeling—is released as public‑domain Prior Art to ensure global accessibility and prevent proprietary enclosure.